Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT06819891
Registration number
NCT06819891
Ethics application status
Date submitted
6/02/2025
Date registered
11/02/2025
Date last updated
16/07/2025
Titles & IDs
Public title
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
Query!
Scientific title
A Phase III, Multicenter, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Induction Therapy With RO7790121 in Patients With Moderately to Severely Active Crohn's Disease
Query!
Secondary ID [1]
0
0
2024-513054-30-00
Query!
Secondary ID [2]
0
0
GA45332
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
SIBERITE-2
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Moderately to Severely Active Crohns Disease
0
0
Query!
Condition category
Condition code
Oral and Gastrointestinal
0
0
0
0
Query!
Inflammatory bowel disease
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Other inflammatory or immune system disorders
Query!
Oral and Gastrointestinal
0
0
0
0
Query!
Crohn's disease
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Afimkibart
Treatment: Drugs - Placebo
Experimental: Afimkibart - Participants will receive afimkibart intravenously (IV) followed by afimkibart subcutaneous (SC) injection.
Placebo comparator: Placebo - Participants will receive placebo IV followed by afimkibart SC injection.
Treatment: Drugs: Afimkibart
Afimkibart will be administered as IV infusion. Afimkibart will be administered as SC injection.
Treatment: Drugs: Placebo
Placebo matching IV afimkibart.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of Participants with Clinical Remission per Crohn's Disease Activity Index (CDAI) Score
Query!
Assessment method [1]
0
0
Percentage of participants achieving a CDAI score of \<150. The index is a weighted sum of scores on eight components: number of liquid or soft stools (stool frequency), abdominal pain, general well-being, number of complications, use of anti-diarrheal medication, presence of an abdominal mass, hematocrit, and percentage deviation from standard body weight. CDAI generally ranges from 0 to roughly 600, with higher values indicating greater activity.
Query!
Timepoint [1]
0
0
At Week 12
Query!
Primary outcome [2]
0
0
Percentage of Participants with Endoscopic Response
Query!
Assessment method [2]
0
0
Percentage of participants achieving a decrease in Simple Endoscopic Score for Crohn's Disease (SES-CD) of \>=50% from baseline. The SES-CD is a composite of four features of endoscopic activity (presence and size of ulcers, extent of ulcerated surface, extent of affected and presence and type of narrowings or stenosis) in up to five ileocolonic segments (terminal ileum, right colon, transverse colon, sigmoid and left colon, and rectum). Each feature is scored on a scale from 0 to 3, giving segment subscores of 0 to 12 points and a total SES-CD range of 0-60, with a higher value indicating greater severity.
Query!
Timepoint [2]
0
0
At Week 12
Query!
Secondary outcome [1]
0
0
Percentage of Participants with Symptomatic Remission
Query!
Assessment method [1]
0
0
Percentage of participants with the daily number of liquid or very soft stools \<=2.8 and the average of daily abdominal pain scores in the past week \<=1, with neither being greater than baseline.
Query!
Timepoint [1]
0
0
At Week 12
Query!
Secondary outcome [2]
0
0
Percentage of Participants with Endoscopic Remission
Query!
Assessment method [2]
0
0
Percentage of participants with an SES-CD of 0 to 4 with a decrease from baseline \>=2 and no subscore \>1.
Query!
Timepoint [2]
0
0
At Week 12
Query!
Secondary outcome [3]
0
0
Percentage of Participants with Ulcer-free Endoscopy
Query!
Assessment method [3]
0
0
Percentage of participants with an SES-CD ulcerated surface subscore of 0.
Query!
Timepoint [3]
0
0
At Week 12
Query!
Secondary outcome [4]
0
0
Average of Daily Number of Liquid or Very Soft Stools in the Past Week (SF)
Query!
Assessment method [4]
0
0
Daily average number of liquid or very soft stools over 7 days.
Query!
Timepoint [4]
0
0
Baseline through Week 12
Query!
Secondary outcome [5]
0
0
Average of Daily Abdominal Pain Scores in the Past Week (APS)
Query!
Assessment method [5]
0
0
The average daily rating of abdominal pain in the past 7 days. The pain is assessed on a scale of 0-3 with 0 indicating no pain and 3 indicating severe pain.
Query!
Timepoint [5]
0
0
Baseline through Week 12
Query!
Secondary outcome [6]
0
0
Bowel Urgency
Query!
Assessment method [6]
0
0
Bowel urgency from baseline through week 12 and. Bowel urgency is a single-item self-reported assessment of sudden or immediate need to have a bowel movement in the past 24 hours. The item response is reported on a 4-point Likert scale, from "None" to "Severe."
Query!
Timepoint [6]
0
0
Baseline to Week 12
Query!
Secondary outcome [7]
0
0
Fatigue
Query!
Assessment method [7]
0
0
Fatigue, as measured by the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), from baseline to Week 12. FACIT-F is a 13-item self-reported assessment of fatigue. Each item response option indicates the degree to which a given statement describing the level or impact of fatigue applies in the past 7 days. Response options are graded on a 5-point Likert-type scale, from "Not at all" to "Very much."
Query!
Timepoint [7]
0
0
Baseline to Week 12
Query!
Secondary outcome [8]
0
0
Inflammatory Bowel Disease Questionnaire (IBDQ) Score
Query!
Assessment method [8]
0
0
Change in IBDQ score from baseline to week 12. The IBDQ is a 32-item questionnaire that measures four domains: bowel symptoms (10 questions); systemic symptoms (5 questions); emotional function (12 questions); and social function (5 questions). The total score ranges from 32-224, with a higher score indicating a better quality of life.
Query!
Timepoint [8]
0
0
Baseline to Week 12
Query!
Secondary outcome [9]
0
0
Percentage of Participants with Clinical Remission: Among Biomarker-Defined Subgroups of Participants
Query!
Assessment method [9]
0
0
Percentage of participants achieving a CDAI score of \<150 at Week 12 in biomarker-defined subgroups. The index is a weighted sum of scores on eight components: number of liquid or soft stools (stool frequency), abdominal pain, general well-being, number of complications, use of anti-diarrheal medication, presence of an abdominal mass, hematocrit, and percentage deviation from standard body weight. CDAI generally ranges from 0 to roughly 600, with higher values indicating greater activity.
Query!
Timepoint [9]
0
0
At Week 12
Query!
Secondary outcome [10]
0
0
Percentage of Participants with Endoscopic Response: Among Biomarker-Defined Subgroups of Participants
Query!
Assessment method [10]
0
0
Percentage of participants achieving a decrease in SES-CD of \>=50% from baseline. The SES-CD is a composite of four features of endoscopic activity (presence and size of ulcers, extent of ulcerated surface, extent of affected and presence and type of narrowings or stenosis) in up to five ileocolonic segments (terminal ileum, right colon, transverse colon, sigmoid and left colon, and rectum). Each feature is scored on a scale from 0 to 3, giving segment subscores of 0 to 12 points and a total SES-CD range of 0-60, with a higher value indicating greater severity.
Query!
Timepoint [10]
0
0
At Week 12
Query!
Secondary outcome [11]
0
0
Percentage of Participants with Clinical Response
Query!
Assessment method [11]
0
0
Percentage of participants with a decrease \>=100 in CDAI from baseline.
Query!
Timepoint [11]
0
0
At Week 12
Query!
Secondary outcome [12]
0
0
Percentage of Participants with Symptomatic Response
Query!
Assessment method [12]
0
0
Percentage of participants with a decrease \>=30% in both SF and APS, with neither being greater than baseline.
Query!
Timepoint [12]
0
0
At Week 12
Query!
Secondary outcome [13]
0
0
Overall Change in CD Symptoms
Query!
Assessment method [13]
0
0
Overall change in CD symptoms, as measured by the Patient Global Impression of Change (PGIC) from baseline to Weeks 2, 6 and 12. PGIC measures overall change in Crohn's disease symptoms from "Much better" to "Much worse".
Query!
Timepoint [13]
0
0
Baseline to Weeks 2, 6 and 12
Query!
Secondary outcome [14]
0
0
Overall Severity in CD Symptoms
Query!
Assessment method [14]
0
0
Overall severity in CD symptoms, as measured by the Patient Global Impression of Severity (PGIS) from baseline to Weeks 2, 6 and 12. PGIS measures severity of Crohn's disease symptoms from "None" to "Very severe".
Query!
Timepoint [14]
0
0
Baseline to Weeks 2, 6 and 12
Query!
Secondary outcome [15]
0
0
Change in General Well-being
Query!
Assessment method [15]
0
0
The average daily rating of general well-being in the past 7 days. Well-being is assessed on a scale of 0-4 with 0 indicating generally well and 4 indicating terrible.
Query!
Timepoint [15]
0
0
Baseline through Week 12
Query!
Secondary outcome [16]
0
0
Incidence and Severity of Adverse Events (AEs)
Query!
Assessment method [16]
0
0
Incidence and severity of AEs, including serious AEs, AEs leading to treatment discontinuation and AEs of special interest.
Query!
Timepoint [16]
0
0
Up to 30 Weeks after Baseline
Query!
Secondary outcome [17]
0
0
Presence of Draining Fistulas
Query!
Assessment method [17]
0
0
Fistulas will be assessed for draining or closed status, where closed fistulas will be assessed by the investigator as no longer draining.
Query!
Timepoint [17]
0
0
Baseline through Week 12
Query!
Eligibility
Key inclusion criteria
* Confirmed diagnosis of CD
* Moderately to severely active CD
* Bodyweight >= 40 kilogram (kg)
* Demonstrated inadequate response, loss of response and/or intolerance to at least one protocol-specified conventional or advanced CD therapy
* Males and females of childbearing potential must meet protocol criteria for contraception requirements
Query!
Minimum age
16
Years
Query!
Query!
Maximum age
80
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Current diagnosis of ulcerative colitis (UC) or indeterminate colitis, ischemic colitis, infectious colitis, radiation colitis, microscopic colitis
* Participant with a history of >= 3 bowel resections (> 2 missing segments of the 5 following segments: terminal ilelium, right colon, transverse colon, sigmoid and left colon, and rectum)
* Diagnosis of short gut or short bowel syndrome
* Presence of an ileostomy, colostomy or ileoanal pouch
* Participants with symptomatic bowel strictures, fulminant colitis, or toxic megacolon
* Presence of abdominal or perianal abscess
* Presence of rectovaginal, enterovaginal, high output enterocutaneous fistula, enterovesical fistulas or perianal fistulas with >3 openings
* Participants with symptomatic bowel strictures, fulminant colitis, or toxic megacolon
* Current diagnosis or suspicion of primary sclerosing cholangitis
* Pregnancy or breastfeeding, or intention of becoming pregnant during the study
* Any past or current evidence of cancer of gastrointestinal tract, definite low-grade or high-grade colonic dysplasia
* History of non-gastrointestinal cancer, with the exception of adequately treated non-metastatic basal cell or squamous cell skin cancer or in situ cervical cancer
* Evidence of infection with Clostridioides difficile (C. difficile; formerly known as Clostridium difficile), cytomegalovirus (CMV), human immunodeficiency virus (HIV), Hepatitis B (HBV), Hepatitis C (HCV) during screening
* Has evidence of active tuberculosis (TB), latent TB not successfully treated (per local guidance) or inadequately treated TB
* Has received protocol-specified prohibited medicines, including known exposure to any type of anti-TL1A therapy
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
12/05/2025
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
31/12/2028
Query!
Actual
Query!
Sample size
Target
425
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD
Query!
Recruitment hospital [1]
0
0
Macquarie University Hospital - Macquarie Park
Query!
Recruitment hospital [2]
0
0
Coral Sea Clinical Research Institute - Mackay
Query!
Recruitment postcode(s) [1]
0
0
2109 - Macquarie Park
Query!
Recruitment postcode(s) [2]
0
0
4740 - Mackay
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Colorado
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Florida
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Louisiana
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Maryland
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Michigan
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
New York
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
North Carolina
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Ohio
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Texas
Query!
Country [11]
0
0
Austria
Query!
State/province [11]
0
0
Wels
Query!
Country [12]
0
0
Belgium
Query!
State/province [12]
0
0
Brussels
Query!
Country [13]
0
0
Belgium
Query!
State/province [13]
0
0
Brussel
Query!
Country [14]
0
0
Belgium
Query!
State/province [14]
0
0
Bruxelles
Query!
Country [15]
0
0
Canada
Query!
State/province [15]
0
0
Ontario
Query!
Country [16]
0
0
Chile
Query!
State/province [16]
0
0
Santiago
Query!
Country [17]
0
0
China
Query!
State/province [17]
0
0
Jiangxi
Query!
Country [18]
0
0
China
Query!
State/province [18]
0
0
Yunnan
Query!
Country [19]
0
0
China
Query!
State/province [19]
0
0
Zhejiang
Query!
Country [20]
0
0
China
Query!
State/province [20]
0
0
Beijing
Query!
Country [21]
0
0
China
Query!
State/province [21]
0
0
Chengdu
Query!
Country [22]
0
0
China
Query!
State/province [22]
0
0
Guangzhou
Query!
Country [23]
0
0
China
Query!
State/province [23]
0
0
Haikou
Query!
Country [24]
0
0
China
Query!
State/province [24]
0
0
Huizhou
Query!
Country [25]
0
0
China
Query!
State/province [25]
0
0
Nanchang City
Query!
Country [26]
0
0
China
Query!
State/province [26]
0
0
Shanghai
Query!
Country [27]
0
0
China
Query!
State/province [27]
0
0
ShenYang
Query!
Country [28]
0
0
China
Query!
State/province [28]
0
0
Shijiazhuang City
Query!
Country [29]
0
0
China
Query!
State/province [29]
0
0
Xi'an City
Query!
Country [30]
0
0
China
Query!
State/province [30]
0
0
Zhenjiang
Query!
Country [31]
0
0
Colombia
Query!
State/province [31]
0
0
Bogota
Query!
Country [32]
0
0
Colombia
Query!
State/province [32]
0
0
Monteria
Query!
Country [33]
0
0
Czechia
Query!
State/province [33]
0
0
Hradec Kralove
Query!
Country [34]
0
0
Czechia
Query!
State/province [34]
0
0
Ostrava - Poruba
Query!
Country [35]
0
0
Czechia
Query!
State/province [35]
0
0
Praha 7
Query!
Country [36]
0
0
France
Query!
State/province [36]
0
0
Chambray les Tours
Query!
Country [37]
0
0
France
Query!
State/province [37]
0
0
Clermont Ferrand
Query!
Country [38]
0
0
France
Query!
State/province [38]
0
0
Créteil
Query!
Country [39]
0
0
France
Query!
State/province [39]
0
0
La Roche Sur Yon
Query!
Country [40]
0
0
France
Query!
State/province [40]
0
0
Lille
Query!
Country [41]
0
0
France
Query!
State/province [41]
0
0
Limoges
Query!
Country [42]
0
0
France
Query!
State/province [42]
0
0
Montpellier
Query!
Country [43]
0
0
France
Query!
State/province [43]
0
0
Neuilly sur Seine
Query!
Country [44]
0
0
France
Query!
State/province [44]
0
0
Paris
Query!
Country [45]
0
0
France
Query!
State/province [45]
0
0
Pierre-Benite
Query!
Country [46]
0
0
France
Query!
State/province [46]
0
0
Vandoeuvre-les-nancy
Query!
Country [47]
0
0
Hungary
Query!
State/province [47]
0
0
Szombathely
Query!
Country [48]
0
0
Italy
Query!
State/province [48]
0
0
Lazio
Query!
Country [49]
0
0
Poland
Query!
State/province [49]
0
0
Bydgoszcz
Query!
Country [50]
0
0
Poland
Query!
State/province [50]
0
0
Knurów
Query!
Country [51]
0
0
Poland
Query!
State/province [51]
0
0
Kraków
Query!
Country [52]
0
0
Poland
Query!
State/province [52]
0
0
Lublin
Query!
Country [53]
0
0
Poland
Query!
State/province [53]
0
0
Pozna?
Query!
Country [54]
0
0
Poland
Query!
State/province [54]
0
0
Sopot
Query!
Country [55]
0
0
Poland
Query!
State/province [55]
0
0
Warszawa
Query!
Country [56]
0
0
Poland
Query!
State/province [56]
0
0
Wroc?aw
Query!
Country [57]
0
0
Portugal
Query!
State/province [57]
0
0
Braga
Query!
Country [58]
0
0
Portugal
Query!
State/province [58]
0
0
Lisboa
Query!
Country [59]
0
0
Portugal
Query!
State/province [59]
0
0
Porto
Query!
Country [60]
0
0
Spain
Query!
State/province [60]
0
0
Zaragoza
Query!
Country [61]
0
0
United Kingdom
Query!
State/province [61]
0
0
Bury
Query!
Country [62]
0
0
United Kingdom
Query!
State/province [62]
0
0
Llanrhystud
Query!
Country [63]
0
0
United Kingdom
Query!
State/province [63]
0
0
London
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Hoffmann-La Roche
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/industry
Query!
Name [1]
0
0
Chugai Pharmaceutical
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This Phase III, multicenter, double-blind, placebo-controlled study will evaluate the efficacy and safety of induction therapy with Afimkibart (also known as RO7790121) in participants with moderately to severely active Crohn's disease (CD).
Query!
Trial website
https://clinicaltrials.gov/study/NCT06819891
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Clinical Trials
Query!
Address
0
0
Hoffmann-La Roche
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Reference Study ID Number: GA45332 https://forpatients.roche.com/
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
888-662-6728 (U.S. and Canada)
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Data sharing statement
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT06819891
Download to PDF